Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 27, 2025, the fund's latest net value is 1.5582 yuan, reflecting a growth of 0.85% [1] - The fund's one-month return is 3.03%, ranking 1106 out of 4652 in its category, while its six-month return is 0.23%, ranking 3299 out of 4496 [1] - Year-to-date, the fund has achieved a return of 2.43%, ranking 2140 out of 4544 [1] Group 2 - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

中国经济网北京5月27日讯 20日，智通财经发布《名单炸裂？64位基金经理近三年跑输基准超10%，还 有百亿老将在列》一文。文中称，据济安金信统计，截至今年4月30日，市场上有64位基金经理旗下全 部基金的近三年年化收益率均跑输基准超10%（各类份额合并计算，且仅统计成立满三年的产品）。其 中，广发基金郑澄然、摩根士丹利基金王大鹏、信达澳亚基金邹运共有4只基金管理时长超三年，且4只 基金的近三年年化收益率均跑输基准10%。 从摩根士丹利基金王大鹏目前正在管理的基金来看，包括大摩沪港深精选混合A/C、大摩健康产业混合 A/C、大摩消费领航混合、大摩卓越成长混合，且时间最短3年，最长超过8年。 但在任职回报上，大摩沪港深精选混合A/C与大摩健康产业混合C，均遭遇大幅下跌，值得注意的是这 两只基金的起始管理时间均在2021年内，且重仓股均以医药股为主。今年一季报显示，大摩沪港深精选 混合的前十大重仓股为科伦博泰生、药明康德（603259）、恒瑞医药（600276）、泽璟制药、信达生 物、百济神州、康诺亚、康龙化成（300759）、贝达药业（300558）、昭衍新药（603127）。大摩健康 产业混合C的前十大重仓股 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of May 26, 2025, the latest net value of the fund is 1.6119 yuan, reflecting a decrease of 1.60%. The fund's one-month return is 3.10%, six-month return is 0.62%, and year-to-date return is 2.75, with respective rankings of 937 out of 3909, 2718 out of 3796, and 1764 out of 3832 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan. The fund manager is Ms. Ge Lan [1] - Ms. Ge Lan has a background in biomedical engineering with a Ph.D. from Northwestern University and has held various research and fund management positions since joining China Europe Fund Management in October 2014 [2]

2025.05. 26 【今日推荐】 俄大使馆遭无人机袭击 当地时间25日，俄罗斯驻瑞典外交使团称，一架携带颜料的无人机袭击了俄罗斯驻瑞典大使馆。据 悉，无人机在夜间向使馆主入口前的平台投掷了一个装有颜料的玻璃容器。 市场监管总局：我国平台经济监管政策体系进一步完善 市场监管总局价监竞争局有关负责同志就《网络交易平台收费行为合规指南（征求意见稿）》答记者 问：总体上看，《指南》的出台，标志着我国平台经济监管政策体系的进一步完善。《指南》以问题 为导向，针对纠治平台收费不透明、不合理等问题提出了具体要求。同时，还强调平台企业的自我规 范、自我监督，提高平台企业落实合规管理主体责任的主动性，推动形成政府监管与企业自律相结合 的治理格局。《指南》对保障平台内经营者知情权、选择权等合法权益作出明确规定，鼓励平台采取 多种措施降低经营者负担，提供让利或减免扶持，对平台内经营者有关收费问题的关切也要及时予以 反馈。未来，随着《指南》的落地实施，将有助于平台企业优化收费合规建设，推动行业健康发展， 构建平台和平台内经营者和谐共生的良好生态。 国乒4金收官！"双曼"组合夺冠！ 当地时间5月25日，2025年多哈世乒赛完成全部 ...

①MSCI中国指数调整将生效；②5月PMI数据将公布；③华为将举行尊界S800发布会。 除MSCI中国指数以外，MSCI中国A股在岸指数的成分股名单也有所调整，增加成分股8只，包括翱捷科技-U、中国卫通、海思科、杭钢股份、艾力斯、百 利天恒、拓维信息、芯原股份。调整结果将于5月30日收盘后生效。 5月PMI数据将公布 5月31日，国家统计局将公布5月PMI数据。据国家统计局，4月份，制造业采购经理指数为49.0%，比上月下降1.5个百分点；非制造业商务活动指数和综合 PMI产出指数分别为50.4%和50.2%，继续保持在扩张区间。 国家统计局服务业调查中心高级统计师赵庆河指出，总体看，综合PMI产出指数自2023年1月以来始终位于临界点以上，我国经济总体产出持续扩张，长期 向好的基本面没有改变。受外部环境急剧变化等因素影响，4月份制造业采购经理指数有所回落，但高技术制造业等相关行业继续保持扩张，以内销为主的 制造业企业生产经营总体稳定。 【重磅新闻】 MSCI中国指数调整将生效 日前，明晟公司（MSCI）公布了5月份指数审议结果。在本次调整中，MSCI中国指数新纳入芯原股份、百利天恒、惠泰医疗、光线传媒、海思 ...

Core Insights - Shenzhen has established its first pharmaceutical and medical device industry overseas joint venture to enhance global market access and accelerate the internationalization of local enterprises [1][2] Group 1: Industry Overview - Shenzhen's pharmaceutical and medical device exports are projected to lead major cities in China in 2024, accounting for 12.9% of the national total [1] - The total export value of medical devices from Shenzhen reached 29.8 billion yuan, with a year-on-year growth of 12.3%, representing 21.3% of the national export share [1] - Pharmaceutical exports from Shenzhen totaled 11.5 billion yuan, with a continuous increase in national share, reaching 6.4% in 2024 [1] Group 2: Joint Venture Structure - The joint venture is initiated by leading companies such as Kexing Pharmaceutical and Mindray Medical, along with other prominent firms like Health元 and Haipru [2] - It includes collaboration with professional service institutions in insurance, consulting, legal, and logistics sectors to create a comprehensive support ecosystem for overseas expansion [2] - The joint venture will establish specialized committees for pharmaceutical and medical device exports, facilitating access to international resources and market entry [2] Group 3: Future Initiatives - The joint venture plans to conduct a series of activities including brand promotion, training, and participation in international exhibitions to showcase Shenzhen's pharmaceutical and medical device innovations [2] - It aims to organize training on legal regulations, product registration, and market analysis, enhancing the capabilities of local enterprises for international operations [2] - The initiative will focus on collective participation in international exhibitions across regions such as Europe, South America, and Central Asia to enhance the global visibility of Shenzhen's pharmaceutical and medical device industry [2]

Core Viewpoint - The announcement details the unlocking of 3,172,332 restricted shares of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., representing 0.25% of the company's total share capital as of the announcement date [1][19][25]. Summary by Relevant Sections Restricted Stock Incentive Plan - The company has completed the necessary approval procedures for the 2021 restricted stock incentive plan, including independent opinions from directors and verification from the supervisory board [1][2][4]. - The plan was approved by the State-owned Assets Supervision and Administration Commission, allowing the implementation of the restricted stock incentive plan [2]. Unlocking Conditions - The second unlocking period for the initially granted restricted shares is set to occur after 36 months from the registration date, allowing for the release of one-third of the granted shares [11][19]. - The conditions for unlocking include no negative audit opinions on financial reports and compliance with performance metrics, such as a compound annual growth rate of at least 10% for net profit attributable to shareholders [11][12][19]. Share Capital Changes - Following the completion of the restricted stock grant registration, the total number of shares increased from 978,900,000 to 987,140,000 shares [4][19]. - The total number of shares after the unlocking will be adjusted accordingly, with the total share capital reaching 1,284,298,685 shares post-unlocking [24][25]. Performance Assessment - The performance assessment for unlocking the shares requires that the individual performance of the incentive recipients meets certain criteria, with a minimum performance rating of C [17][19]. - The company has outlined specific performance metrics that must be achieved for the unlocking of shares, including total asset turnover rates and net profit growth compared to industry averages [12][14][19]. Legal and Compliance - The supervisory board and legal advisors have confirmed that the unlocking of shares complies with relevant laws and regulations, ensuring that the rights of shareholders are protected [25][26]. - The company is required to fulfill its disclosure obligations regarding the unlocking of shares as per regulatory requirements [26].

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 21, 2025, the latest net value of the fund is 1.6359 yuan, reflecting a growth of 1.36% [1] - The fund's one-month return is 4.85%, ranking 1834 out of 4645 in its category, while the three-month return is 0.17%, ranking 1678 out of 4590 [1] - Year-to-date, the fund has achieved a return of 4.28%, with a ranking of 2331 out of 4544 [1] Group 2 - The top ten stock holdings of the China Europe Medical Health Mixed A Fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

股票代码：000999 股票简称：华润三九 编号：2025—046 华润三九医药股份有限公司 关于 2021 年限制性股票激励计划首次授予部分第二个解锁期解 除限售股份上市流通的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1. 本次解除限售股份涉及激励对象 240 名，可解除限售的限制性股票数量为 3,172,332 股，占截至本公告日公司总股本的 0.25%； 2. 本次限售股份可上市流通日为 2025 年 5 月 26 日（星期一）。 华润三九于 2025 年 5 月 14 日召开董事会 2025 年第八次会议、监事会 2025 年第五次会 议，审议通过了《关于 2021 年限制性股票激励计划首次授予部分第二个解锁期解锁条件成 就的议案》。具体内容详见 2025 年 5 月 15 日公司刊登于《证券时报》《中国证券报》《上 海证券报》及巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 截至本公告披露日，公司已于中国证券登记结算有限责任公司深圳分公司办理完毕公司 2021 年限制性股票激励计划（以下简称"本激励计划" ...

Group 1 - The core viewpoint of the articles highlights the rising popularity and market performance of traditional Chinese medicine (TCM) and related ETFs, driven by increasing health awareness among consumers and supportive government policies [1][2]. - The 中证中药指数 (CSI TCM Index) has shown a positive trend, with a 0.77% increase as of May 21, 2025, and significant growth in its constituent stocks, such as 红日药业 (Hongri Pharmaceutical) up by 6.41% [1]. - The 中药ETF (TCM ETF) has also performed well, with a 0.92% increase and a cumulative rise of 4.44% since May, indicating strong investor interest and market engagement [1]. Group 2 - The report from 国泰君安 (Guotai Junan) emphasizes that strong policy support is expected to drive high-quality development in the TCM sector, benefiting leading companies with resources, technology, and brand advantages [2]. - The CSI TCM Index includes major TCM companies, with the top ten stocks accounting for 55.71% of the index, indicating a concentrated market structure [2].